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cavity. It often causes symptoms such as chronic pain, most frequently associated with the menstrual
cycle, and infertility, but may also be oligo- or asymptomatic. There is evidence that some ovarian carci-
noma (OC) histotypes, mainly the ovarian clear cell (OCCC) and endometrioid (EnOC) carcinoma, may
arise from endometriosis. The most frequent genomic alterations in these carcinomas are mutations in
the AT-rich interacting domain containing protein 1A (ARID1A) gene, a subunit of the SWI/SNF chro-
matin remodeling complex, and alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR
pathway, which frequently co-occur. In ARID1A deficient cancers preclinical experimental data sug-
gest different targetable mechanisms including epigenetic regulation, cell cycle, genomic instability, the
PI3K/AKT/mTOR pathway, inflammatory pathways, immune modulation, or metabolic alterations as
potential precision oncology approaches. Most of these strategies are relying on the concept of synthetic
lethality in which tumors deficient in ARID1A are more sensitive to the different compounds. Some
of these approaches are currently being or have recently been investigated in early clinical trials. The
remarkably frequent occurrence of these mutations in endometriosis-associated ovarian cancer, the oc-
currence in a relatively young population, and the high proportion of platinum-resistant disease certainly
warrants further investigation of precision oncology opportunities in this population. Furthermore, ad-
vanced knowledge about oncogenic mutations involved in endometriosis-associated ovarian carcinomas
may be potentially useful for early cancer detection. However, this approach may be complicated by the
frequent occurrence of somatic mutations in benign endometriotic tissue as recent studies suggest. In this
narrative review of the current literature, we will discuss the data available on endometriosis-associated
ovarian carcinoma, with special emphasis on epidemiology, diagnosis and molecular changes that could
have therapeutic implications and clinical applicability in the future.
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Abstract: Endometriosis is a benign gynecologic condition affecting up to one woman out of ten of 
reproductive age. It is defined by the presence of endometrial-like tissue in localizations outside of the uterine 
cavity. It often causes symptoms such as chronic pain, most frequently associated with the menstrual cycle, 
and infertility, but may also be oligo- or asymptomatic. There is evidence that some ovarian carcinoma (OC) 
histotypes, mainly the ovarian clear cell (OCCC) and endometrioid (EnOC) carcinoma, may arise from 
endometriosis. The most frequent genomic alterations in these carcinomas are mutations in the AT-rich 
interacting domain containing protein 1A (ARID1A) gene, a subunit of the SWI/SNF chromatin remodeling 
complex, and alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway, which frequently 
co-occur. In ARID1A deficient cancers preclinical experimental data suggest different targetable mechanisms 
including epigenetic regulation, cell cycle, genomic instability, the PI3K/AKT/mTOR pathway, inflammatory 
pathways, immune modulation, or metabolic alterations as potential precision oncology approaches. Most 
of these strategies are relying on the concept of synthetic lethality in which tumors deficient in ARID1A are 
more sensitive to the different compounds. Some of these approaches are currently being or have recently been 
investigated in early clinical trials. The remarkably frequent occurrence of these mutations in endometriosis-
associated ovarian cancer, the occurrence in a relatively young population, and the high proportion of platinum-
resistant disease certainly warrants further investigation of precision oncology opportunities in this population. 
Furthermore, advanced knowledge about oncogenic mutations involved in endometriosis-associated ovarian 
carcinomas may be potentially useful for early cancer detection. However, this approach may be complicated by 
the frequent occurrence of somatic mutations in benign endometriotic tissue as recent studies suggest. In this 
narrative review of the current literature, we will discuss the data available on endometriosis-associated ovarian 
carcinoma, with special emphasis on epidemiology, diagnosis and molecular changes that could have therapeutic 
implications and clinical applicability in the future.
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Introduction
Endometriosis is a benign gynecologic condition affecting 
up to one woman out of ten of reproductive age. It is 
characterized by pain associated with the menstrual 
cycle such as dysmenorrhea, dyspareunia, dyschezia, 
chronic pelvic pain and/or infertility. The prevalence of 
endometriosis in women affected by infertility is particularly 
high, up to 50%. It is an estrogen-dependent disease; 
therefore, it mainly affects women of reproductive age and 
manifestations of endometriosis in the postmenopausal age 
are rare. Nevertheless, certain residues of endometriosis 
may be found incidentally during surgical procedures (1-4). 
There are three clinically distinct forms of endometriosis 
that may occur in combination: peritoneal endometriosis, 
which is characterized by endometriotic implants on the 
surface of the peritoneum and the ovaries, endometriotic 
ovarian cysts (endometrioma) and deep-infiltrating 
endometriosis, which is characterized by a complex solid mass 
comprised of endometriotic and fibromuscular tissue and 
frequently occurs in the rectovaginal septum. In severe cases of 
deep-infiltrating endometriosis, possible intestinal or urological 
complications such as obstruction of the rectosigmoid, bowel 
infiltration, bladder invasion or ureters’ stenosis can occur and 
often require extensive surgical intervention (5). Laparoscopy 
represents the gold standard for diagnosis and surgical 
treatment of endometriosis; however, repeated laparoscopies 
should be avoided when possible. 
Although most women with endometriosis will never 
suffer from cancer related to this benign disease, evidence 
suggested that certain epithelial ovarian cancer (EOC) 
subtypes, specifically ovarian clear cell (OCCC) and 
endometrioid ovarian (EnOC) carcinoma are directly 
related to endometriosis. This link between endometriosis 
and these EOC subtypes has been confirmed at the 
molecular pathology level through the presence of common 
mutations in cancer-associated genes (6,7). Atypical 
endometriosis may be the precursor of these cancers, but 
is not systematically found in all cases of endometriosis-
associated ovarian cancer (EAOC). 
The challenges raised by these cancers are: (I) they 
often affect younger women, to a considerable extent in 
the age span between 35 and 55 years; (II) sonographic 
differentiation between benign endometriotic cysts, 
also called endometrioma or chocolate cysts, and early-
stage cystic OCCC or EnOC may be very challenging. 
A carcinoma may arise from a limited atypical epithelial 
spot in the interior of an endometrioma and is difficult to 
recognize by sonography in its early stage. EnOC represent 
about 10% of EOC, whereas OCCC, with a prevalence of 
5–12%, is geographically more variable and more frequent 
in some Asian countries. EnOC may be low or high grade, 
but OCCC is per definition high-grade ovarian carcinoma 
and has poor prognosis in advanced stages due to early 
platinum-resistance (8-12). 
Benign endometrioma are usually managed surgically 
while preserving the ovary, either by excision of the cyst 
or, in cases where a maximum of ovarian tissue has to be 
preserved to maintain fertility, by fenestration and laser 
ablation of the inside of the endometrioma, for instance 
(Figure 1). In contrast, EAOC must obviously be managed 
surgically by complete salpingo-oophorectomy without 
opening the cystic lesions to avoid intra-abdominal spillage 
of malignant cells (Figure 2). These cases necessitate a 
referral to a center specialized in gynecologic oncology 
and usually require median laparotomy for staging and 
resection of any detectable tumor masses, hysterectomy 
and bilateral salpingo-oophorectomy, omentectomy, and 
a stage-dependent adequate pelvic and para-aortic lymph 
node assessment (13-15). In patients with presumable 
endometriotic cysts, it is crucial to detect the rare cases with 
increased risk of malignant transformation preoperatively in 
order to avoid the intraoperative dissemination of malignant 
cells. This requires a high degree of expertise in transvaginal 
sonography, which is the most useful and accessible 
method in preoperative assessment. Magnetic resonance 
tomography may have additional value in certain cases, but 
is not a standard procedure for preoperative assessment of 
endometrioma. Tumor marker CA-125 may be helpful, but 
its usefulness in the diagnosis of early EAOC is limited due 
to lack of specificity. Indeed, moderate elevations of CA-125 
often occur in women with benign endometriosis without 
any evidence of EOC (16-22). 
In this narrative review of the present literature, we will 
discuss the data available on EAOC, with special emphasis 
on epidemiology, diagnosis and molecular changes that 
have therapeutical implications. As especially OCCC are 
doi: 10.21037/atm-20-3022a
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often associated with early occuring resistance to platinum-
based chemotherapy regimen the rationale is to identify 
targetable molecular key-mechanisms that provide potential 
new opportunities in a precision oncology approach. As 
many of these mechanisms seem to be involved early in 
the pathogenesis of endometriosis-related ovarian cancer a 
better understanding may in future also be an opportunity 
for early cancer detection in these patients. 
The objective of the present review is to provide an 
overview of these key-mechanisms in the development of 
endometriosis-related ovarian cancer and to discuss them 
in a possible clinical context based on recent preclinical and 
early clinical observations.
Scientific articles with relevance for the discussion of 
the topic were searched using PubMed with emphasis on 
articles published over the last decade. The data in this 
review were all obtained from published studies and/or 
publicly available study information. Only articles published 
in English language were included. Written general consent 
of the patients was available for all intraoperative images 
reproduced in this review article. We present the following 
article in accordance with the NARRATIVE REVIEW 
reporting checklist (available at http://dx.doi.org/10.21037/
atm-20-3022a).
Pathogenesis of endometriosis
Different theories have been proposed regarding 
pathogenesis of endometriosis since its first modern 
description by Sampson almost one century ago. There 
are probably various reasons for the development of 
endometriosis, such as anatomical variations leading to 
increased retrograde menstruation, environmental toxins or 
potent estrogens, especially in case of an in utero exposure, 
genetic factors as well as inflammatory mediators such as 
cytokines (3). Most theories regarding pathogenesis of 
endometriosis consider retrograde menstruation as being 
one of the principle factors connected to the development 
of endometriosis. However, retrograde menstruation 
through the natural orifice of the fallopian tubes is found 
in most women and is not sufficient to explain why only 
some women having retrograde menstruation will develop 
endometriosis. Nor does it explain why endometriosis 
can develop in patients without patency of the fallopian 
tubes or after hysterectomy and even in some women with 
congenital absence of uterus such as the Mayer-Rokitansky-
Küster-Hauser (MRKH) syndrome (23). 
Although endometriosis is regarded as a benign disease, 
it shares some features that are classic hallmarks of cancer, 
such as migration and tissue invasion, but in contrast to 
cancer, the misplaced tissue is morphologically resembling to 
normal endometrium. Endometriosis can also lead to lymph-
angiogenesis and endometriotic tissue has been found in 
lymphatic nodes (24,25). Nevertheless, endometriosis is not 
lethal and does not metastasize or progress in the form of an 
expansile tumor mass like cancer (26). 
Treatment modalities of endometriosis include surgical 
excision of endometriotic implants, through laparoscopic 
approach, and hormonal therapies, mainly progestins 
Figure 1 Endometrioma of the left ovary. Endometrioma typically 
contain brown viscous content resembling to melted chocolate, 
reason why they are sometimes also called “chocolate cysts”. The 
surgical treatment of choice consists in the laparoscopic excision or 
fenestration and laser therapy of the cyst with preservation of the 
ovary (Image credits: with special thanks to Dr. Markus Eberhard, 
Schaffhausen, Switzerland).
Figure 2 Early ovarian clear cell carcinoma (OCC). Clear cell 
carcinoma of the right ovary, most probably originating from 
endometriosis. The macroscopic picture in the very early stage may 
be difficult to distinguish from a benign endometrioma or another 
benign ovarian tumor. The preoperative assessment including 
transvaginal sonography and tumor marker CA-125 is important 
in the risk assessment (e.g. according to the IOTA criteria) and 
crucial for the correct surgical therapy of the patient. Arrows: 
various peritoneal endometriotic lesions and old blood deposits.
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(e.g., dienogest), GnRH analogs (e.g., goserelin) or 
GnRH antagonists (e.g., elagolix). Because endometriosis 
is a chronic disease, a prolonged hormonal recurrence 
prophylaxis is necessary, especially in cases with more severe 
endometriosis and/or associated pain (2,27). The risk for 
developing ovarian cancer is generally low for women with 
endometriosis, with a lifetime risk of about 1.9%, but it is 
relatively increased compared to the general population 
(lifetime risk of approximately 1.4%) (21,28).
Recent findings indicate that somatic cancer driver 
mutations in the ARID1A gene are present in a subset of 
endometriosis cases and may be involved in its pathogenesis 
(29-32). Endometriosis is an estrogen-dependent disease. 
The role of ARID1A mutations in regulating estrogen 
receptor signaling may further support its relevance in the 
pathogenesis of endometriosis, as it was recently reported 
in the context of estrogen-receptor-positive breast cancer 
(33,34). 
Epidemiology of endometriosis-associated 
ovarian carcinoma
A possible link between endometriosis and EOC in certain 
cases has been suggested for a long time. It was Sampson 
who described for the first time in 1925 an endometriosis-
associated ovarian endometrioid carcinoma (35). Multiple 
studies have since assessed the incidence of EAOC (36-46). 
In a large register study of 20,686 Swedish women 
hospitalized for endometriosis, the standardized incidence 
ratio for developing ovarian cancer during a mean follow-
up of 11.4 years was 1.9 (95% CI: 1.3–2.8). The risk of 
ovarian cancer was higher in patients with a long history 
of endometriosis (47). In another Swedish register 
study including 64,492 women with endometriosis, the 
standardized incidence ratio was 1.43 (95% CI: 1.19–1.71), 
again with a higher incidence in women with early diagnosis 
and a long history of endometriosis (48). In a pooled meta-
analysis of 13 case-control studies including 7,911 women 
with ovarian cancer and 13,226 controls, the frequency 
of self-reported endometriosis was significantly higher in 
the group with ovarian cancer. This group had an odds 
ratio (OR) of 1.46 (95% CI: 1.31–1.63, P<0.0001) after 
adjustment for the duration of oral contraceptive use as well 
as parity and stratification for age and ethnic origin. The OR 
were significantly increased in the histotypes OCCC (OR 
3.05, 95% CI: 2.43–3.84, P<0.0001), EnOC (OR 2.04, 95% 
CI: 1.67–2.48, P<0.0001) and low-grade serous carcinoma 
(OR 2.11, 95% CI: 1.39–3.20, P<0.0001). No association 
between a history of endometriosis and risk for high-grade 
serous or mucinous carcinoma were found (49). Consistent 
observations were reported by a Danish register study (OR 
1.34, 95% CI: 1.16–1.55), confirming the association with 
the two histotypes EnOC (OR 1.64, 95% CI: 1.09–2.37) 
and OCCC (OR 3.64, 95% CI: 2.36–5.38) (50). In the 
ENOCA population-based cohort study using the Dutch 
nationwide registry of histopathology and cytopathology, 
the incidence of endometrioid and clear-cell ovarian cancer 
in a cohort of 131,450 women with a histological diagnosis 
of endometriosis was compared to an age-matched control 
cohort of 132,654 women with a benign dermal nevus. The 
age-adjusted incidence rate ratio (IRR) was 7.18 (95% CI: 
6.17–8.46) for ovarian cancer in women with endometriosis, 
and there was a strong association with the two subtypes of 
OCCC (with an IRR of 21.34, 95% CI: 14.01–32.51) and 
EnOC (with an IRR of 29.06, 95% CI: 20.66–40.87), all of 
them age adjusted. However, an important subset of these 
patients had a simultaneous diagnosis of endometriosis and 
ovarian cancer in the same surgery, which represented a 
potential bias in the study. Therefore, the authors excluded 
women with diagnosis of endometriosis less than one year 
before diagnosis of ovarian cancer in a subsequent analysis. 
Overall, the recalculated age-adjusted IRR was estimated to 
be 1.08 (95% CI: 0.87–1.35) for ovarian cancer, with still a 
significantly increased risk for the two subtypes of OCCC 
and EnOC. An important observation in this study was that 
the median age at diagnosis of ovarian cancer was earlier, 
with 56 years (IQR 49–63) for women with endometriosis 
compared to 60 years in the control cohort (IQR 53–67). 
This observation suggests that women with endometriosis 
still have an increased risk for developing ovarian cancer 
even if the activity and symptoms of endometriosis drop 
after the onset of menopause (51). In contrast to the evident 
link between endometriosis and ovarian carcinoma, women 
with endometriosis do not seem to be at increased risk 
for endometrial cancer, as reported by a large prospective 
cohort of U.S. nurses (52). The present literature generally 
does not support an increased risk for cancers other than 
EOC in women with endometriosis (53). 
In summary, the lifetime risk for developing ovarian cancer 
is low with approximately 1.9% (as compared to 1.4% for 
the general population) since ovarian cancer is not frequent 
when compared to other cancers (breast, lung, colon, etc...). 
Nevertheless, the risk for a woman with endometriosis to 
develop ovarian cancer is up to 50% higher than in the 
general population. This is particularly true regarding the 
risk for developing the clear cell or endometrioid histotype, 
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where the risk is tripled or doubled, respectively (21). 
Diagnostics in endometriosis and issues for 
early cancer detection
Transvaginal sonography is one of the most valuable 
diagnostic tools in the routine diagnosis of endometrioma 
and suspicious ovarian masses. It is usually complemented 
by serum measurement of the tumor marker CA-125 and, 
in certain circumstances, may be supplemented by other 
imaging techniques such as magnetic resonance tomography 
or computer tomography. The sensitivity and specificity of 
transvaginal sonography is overall comparable to magnetic 
resonance tomography, and it is usually sufficient for the 
preoperative assessment of endometrioma and/or suspicious 
ovarian masses (21).
Recently, the diagnostic possibilities of ultrasound 
imaging have improved considerably, both regarding 
technology and assessment expertise of the sonographer. 
Clinical research collaborations such as the International 
Ovarian Tumour Analysis (IOTA) group and others 
have permitted results that were not possible before for 
ultrasound assessment of suspicious ovarian masses (54-56).
The description of all sonographic criteria that allow 
preoperative assessment of the risk of malignancy in 
endometrioma and other masses of the ovary is beyond the 
scope of this review. It is important to note that a typical 
endometrioma is mostly a unilocular (or multilocular with 
up to four locules) cyst containing a homogeneous “ground-
glass” echogenicity without detectable solid or vascularized 
papillary parts, whereas borderline tumors and carcinoma 
arising from endometrioma generally show a vascularized 
solid component (54). An increased age of 45 years or 
more as well as increased endometrioma size (≥8 cm) were 
independent predictors for the development of ovarian 
cancer in women with endometrioma (43,57,58).
Recent studies have proposed mutation analyses in 
endocervical or preferably intrauterine cell samples for a 
potential early detection of endometrial and ovarian cancer. 
These methods must be further studied regarding their 
clinical validity. However, even if some of these concepts 
should prove to be valid for a peri-/postmenopausal 
population in future, this may likely not be the same for 
a younger population of patients with endometriosis as 
somatic mutations occur more frequently in eutopic and 
ectopic endometrium than previously thought (30,59-62). 
At present, there is no useful screening possibility for EOC 
and this also applies to patients with endometriosis (63-66).
Common pathogenic features of endometriosis 
and associated ovarian carcinoma
Since the discovery in 2010 that mutations in the AT-rich 
interacting domain 1A (ARID1A), encoding an accessory 
subunit of the SWI/SNF chromatin remodeling complex, 
are frequent in OCCC, EnOC and their endometriotic 
precursor lesions, there has been substantial emphasis on 
EAOC and the epigenetic role of the SWI/SNF chromatin 
remodeling complex in carcinogenesis (6,7). Overall, 
SWI/SNF-associated genes are mutated in about 20% 
of all human cancers. Mutations in ARID1A have been 
found in a multitude of different cancers, with the highest 
frequency in OCCC (up to 60%) and EnOC (approx. 30%) 
(6,7,33,34,67-81) (Table 1). 
Table 1 Prevalence of ARID1A mutations in different cancers
Tumor origin Histologic subtype ARID1A mutations frequency References
Ovarian carcinoma clear cell (OCCC) ~60% (6,7,81)
endometrioid (EnOC) ~30%
Endometrial carcinoma endometrioid 29% (68,69,82)
clear cell 26%
serous 18%
Breast cancer (luminal types) 4–35% (33,78,79)
Hepatobiliary carcinoma 10–17% (75-77)
Pancreatic carcinoma 8–45% (70,71)
Gastric carcinoma 8–29% (72-74)
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The ARID1A  gene encodes the protein BRG1-
associated factor 250a (BAF250a or p270), which is part 
of a family of 15 human proteins that contain a typical 
100-amino-acid DNA-binding ARID domain (83). The 
SWI/SNF complexes bind to DNA regions via ARID1A or 
ARID1B, which are two mutually exclusive, nonselective 
DNA binding accessory subunits of the complex, and/or 
through interaction with general or specific transcription 
factors (84,85). Mutations in ARID1A are in general loss-
of-function mutations, including nonsense, frameshift 
and large deletions that lead to a loss of BAF250a protein 
expression (6). Importantly, endometriosis is the first and 
only benign disease in which a loss of ARID1A expression 
has been observed in cases without any evidence for cancer 
(29,30,86-88). Mutations in ARID1A are considered as an 
early event but ARID1A inactivation alone is not sufficient 
for the oncogenic transformation of either the endometrium 
or ovarian surface epithelium. Several other mechanisms 
such as PIK3CA-activating mutations in cooperation 
with loss of ARID1A expression seem to be necessary to 
initiating cancer development (Figure 3) (80,89-94). 
Due to its large size (20 exons) and the distribution of 
mutations across the whole gene, detection of mutations in 
ARID1A by sequencing is quite challenging, especially when 
only a very limited amount of tissue is available, which is 
the case for the epithelial fraction of endometriosis (6,30). 
ARID1A immunohistochemistry has been shown to be an 
excellent surrogate marker for ARID1A mutations (95).
Interestingly there are no known mutually exclusive 
mutations that clearly distinguish OCCC and EnOC, 
Figure 3 Hypothetic model of pathogenesis of endometriosis-associated ovarian carcinoma. Reactive oxygen species (ROS) due to free heme 
and catalytic iron contained in the trapped blood in endometriomas may lead to increased oxidative stress and DNA damage in the epithelial 
layer of endometriomas. This may result in mutations and epigenetic changes, including mutations in the tumor suppressor gene ARID1A 
and possible second-hit mutations as well as activation of the PI3K-AKT-mTOR pathway to escape apoptosis caused by increased oxidative 
stress. The accumulation of oncogenic mutations in atypical endometriosis may ultimately lead to the development of endometriosis-
associated ovarian clear cell (OCC) and endometrioid (EnOC) carcinomas (adapted from Vercellini et al., Hum Reprod, 2011 and Samartzis 
et al., GYNÄKOLOGIE, 2018).
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even though these two histotypes are distinct in their 
morphological and clinical presentation. However, some 
genomic features such as the APOBEC (apolipoprotein B 
mRNA editing enzyme catalytic polypeptide-like) signature 
are found in 26% of OCCC, whereas microsatellite 
instability is more frequent (28%) in EnOC (80,96).
Preclinical studies targeting ARID1A-mutated 
tumors
Since ARID1A mutations cause loss of functions in a tumor-
suppressing mechanism, there is no possibility of directly 
targeting the mutations with a therapeutic intent (97). 
Various preclinical studies suggest the possibility of using 
the synthetic lethality approach, a concept that is best 
known in PARP-inhibitors, to target ARID1A-deficient 
tumors (Figure 4) (98-101). A general overview of different 
preclinically identified therapeutic targets related to 
ARID1A deficiency is provided in Table 2.
In OCCC, ARID1A mutations frequently co-occur 
with mutations that lead to the activation of the PI3K/
AKT signaling pathway, such as loss of PTEN (phosphatase 
and tensin homolog) or gain-of-function mutations of the 
PIK3CA gene, encoding the catalytic subunit, p110α, of 
PI3K (91,119). These changes have also been observed 
in benign and atypical endometriosis adjacent to OCCC 
(6,29,61,120). These observations suggest a cooperative role 
of ARID1A inactivation and PI3K/AKT activation in the 
malignant transformation of the endometriotic precursor 
lesion. A conditional ARID1A knockout was combined 
Figure 4 Therapeutic targeting strategies in ARID1A deficient tumors. Since ARID1A mutations lead to a deficiency in the encoded 
protein, the strategies to target ARID1A mutated tumors use the principle of synthetic lethality. The main approaches are stated in circles 
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with insertion of a mutant PIK3CA allele in a transgenic 
mouse model, leading to the expression of a constitutively 
active catalytic subunit of PI3K and the development 
of highly penetrant ovarian tumors with OCCC-like 
histopathology (115). These results affirmed that ARID1A 
loss and activation of PI3K/AKT functionally cooperate in 
ovarian carcinogenesis, and suggest that ARID1A-deficient 
tumors may be “addicted” to PI3K/AKT oncogenic 
signaling. As a consequence, elements of the PI3K/AKT 
signaling pathway may be good candidate targets for the 
induction of synthetic lethality in tumors with ARID1A 
loss-of-function mutations. In vitro studies have shown 
increased sensitivity and induced apoptosis towards the 
AKT-inhibitors MK-2206 and perifosine, as well as the 
Pan-PI3K-inhibitor buparlisib, in ARID1A-depleted breast 
cancer and OCCC cell lines (100,106).  The mTORC1/2 
inhibitor AZD8055 showed a significant sensitivity in 
OCCC cell lines and patient-derived xenografts which 
however was independent of the ARID1A mutation 
status and PI3K/AKT/mTOR alterations (108). EZH2 
inhibition led to synthetic lethality in ARID1A-mutated 
tumors, in which PIK3IP1, an inhibitor of PI3K/Akt, 
plays a major role (106,107). As another epigenetic target, 
a lethal relationship was identified between ARID1A loss 
and inhibition of HDAC6 using the HDAC6-inhibitor 
ACY1215 (103). 
Other in vitro approaches such as the depletion of 
ARID1B in ARID1A-mutated tumor cells demonstrated 
strong synthetic lethality, since ARID1A and ARID1B 
are mutually exclusive subunits of the SWI/SNF complex 
and the survival of ARID1A-deficient cells depends 
on the presence of ARID1B in the residual SWI/SNF 
complex (105).
Without a doubt, chronic inflammation is a central 
process in EAOC, with proinflammatory cytokines playing 
an important role in benign endometriosis. ARID1A 
has been shown to protect against inflammation-driven 
tumorigenesis. The combination of ARID1A loss and 
Table 2 Potential targets in ARID1A-mutated tumors in preclinical studies
Pathway Target Drug class Drugs investigated Ref.
Epigenetic HDAC2 HDAC inhibitor Vorinostat (102)
HDAC6 HDAC inhibitor Ricolinostat (ACY1215) (103)
BRD2 BET inhibitor iBET-762 (104)
HDAC1, BRD4 BET inhibitor (BRD4-i) Pexidartinib (PLX2853) (34)
ARID1B ARID1B knockout non targetable in vivo (105)
PIK3IP1 EZH2 inhibitor Tazemetostat (106,107)
PI3K/AKT/mTOR
PI3K PI3K-inhibitor Buparlisib (100,106)
AKT AKT-inhibitor Perifosine, MK-2206 (100)
mTOR mTORC1/2 inhibitor AZD8055 (in OCCC, ARID1A-independent)) (108)
mTOR + PI3K Dual-PI3K-/mTOR-i Dactolisib (BEZ235), DS-7423 (109,110)
Cell cycle YES1 (SRC family) Tyrosine kinase inhibitor Dasatinib (99,111,112)
Genomic instability TOP2A ATR inhibitor Berzosertib (VX-970) (113)
PARP PARP inhibitor Olaparib, Rucaparib, Veliparib, Talazoparib 
(BMN673)
(114)
Inflammatory IL-6/IL-6-receptor Anti-IL-6 agents Tocilizumab (anti-IL-6-receptor ab), 
Siltuximab (anti-IL-6 ab)
(115)





Immune modulation PD-1 PD-1 inhibitor Pembrolizumab, Nivolumab (117)
MMR/MSH2 deficiency (118)
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PIK3CA activating mutations led to the development of 
OCCC through sustained IL-6 production. Knockdown of 
IL6 led to significantly smaller tumors. High levels of IL-6, 
measured in the serum or by IHC are associated with poor 
outcome in OCCC (121,122). Thus, anti-IL-6 therapies, 
which are already used in the clinics for rheumatologic 
disease, may show a potential activity in ARID1A-mutated 
ovarian cancer (115). 
There is evidence suggesting a role of immune 
checkpoint inhibitors in tumors harboring mutations in 
components of the SWI/SNF complex. Recent treatment 
successes have been reported in small-cell carcinoma of 
the ovary, hypercalcemic type (SCCOHT), which is a 
highly aggressive monogenic cancer driven by SMARCA4 
mutations, affecting the catalytic ATPase subunit 
SMARCA4/BRG1 of the SWI-SNF complex. These tumors 
responded well to treatment with anti-PD1 immunotherapy 
despite a low mutation burden (117). In clear cell renal cell 
carcinoma, clinical benefit from anti-PD1 was associated 
with loss-of-function mutations in the PBRM1 gene, which 
encodes a subunit of the PBAF form of the SWI-SNF 
complex (123). In the early clinical trials with anti-PD1 in 
EOC, the highest response rates were observed in OCCC 
(124,125). Together, these observations support further 
investigation of immune checkpoint inhibitors in OCCC 
and the predictive value of ARID1A mutations (117). 
Besides genes’ regulation, the SWI/SNF complex has 
a role in the DNA damage repair processes. The complex 
often localizes to sites of DNA double-strand breaks 
and facilitates the phosphorylation of histone H2AX via 
ATM/ATR (126). Treatment with the ATR-inhibitor 
berzosertib (VX-970) resulted in more than three times 
effective response in various ARID1A-deficient cell lines 
including OCCC, and sensitivity towards ATR-inhibition 
was observed in ARID1A mutant xenograft mouse models. 
ARID1A loss was shown to result in accumulation of 
cells in G2/M. Treatment with ATR inhibitors reversed 
cells accumulation in G2/M and resulted in an increased 
chromosomal instability and apoptosis (113). It is important 
to note that ARID1A-deficient tumors counterintuitively 
typically display less copy number alterations than 
ARID1A wild-type tumors across various cancer types. 
This seemingly increased genomic stability is the result of 
defects in telomere cohesion in ARID1A-deficient tumors 
leading to a continuous selection process against genetically 
instable cancer cells and this mechanism amongst others 
significantly relies on the ATR checkpoint (127). 
A drug screening study of 68 clinically approved or late-stage 
clinically developed inhibitors identified dasatinib, a SRC, ABL 
and C-KIT inhibitor, as being a specific inhibitor in ARID1A-
mutated OCCC cell lines. This was confirmed in ARID1A 
knockout cell lines. The study identified YES1, an SRC family 
protein, as being the most selective target in ARID1A-deficient 
OCCC tumor cells. Dasatinib induced cell cycle arrest in G1 
and caspase activity in ARID1A-mutant tumor cells (99). 
Last but not least, it has been shown that SWI/SNF 
function is required for oxidative stress resistance (128,129). 
Oxidative stress induced by reactive oxygen species (ROS) 
plays an important role through the abundance of free heme 
and catalytic iron in endometrioma and probably plays a 
central role in the pathogenesis of EAOC (130). ARID1A-
mutant OCCC and endometrial cancer cell lines were five 
to six times more sensitive towards the ROS-inducing agent 
elesclomol compared to ARID1A-wildtype cancer cell lines, 
resulting in increased ROS-levels and apoptosis (131). 
Ogiwara et al. demonstrated a link between ARID1A and 
glutathione metabolism that is mediated by the regulation 
of the cystine/glutamate transporter XCT, revealing that 
decreased glutathione synthesis is a metabolic dependency 
of cancers with ARID1A-inactivating mutations (116). 
This complex interaction between epigenetics and the 
glutathione synthesis metabolic pathway opens new insights 
into the mechanisms of tumor initiation, progression 
and drug resistance. This may open great therapeutic 
opportunities, but the complexity of these interactions will 
have to be better understood in order to develop properly 
tailored glutathione synthesis inhibitors (132,133).
Current clinical trials
Targeting of sustained proliferative pathways, such as 
the PI3K/AKT/mTOR pathway and the YES1/SRC 
tyrosine kinase pathway, or metabolic alterations, such as 
the glutathione biogenesis pathway, in ARID1A-deficient 
CCOC may be interesting options for future clinical 
trials (134). Various agents showing synthetic lethality 
in the ARID1A mutant context are currently in clinical 
development. An overview of current clinical trials mainly 
regarding OCCC or relevant for EAOC is available in 
Table 3. In addition to its potential role as a predictive 
biomarker in cancer treatments, ARID1A mutations 
have also been investigated for other purposes such as 
e.g., early cancer detection or in other biomarker studies 
(Table 4). Some studies have also assessed ARID1A as a 
potential prognostic marker in ovarian cancer correlating 
it to the overall survival and resistance to platinum-
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Table 3 Current clinical trials in gynecological cancer using an ARID1A-related treatment approach (www.clinicaltrials.gov)
Study title 
(acronym)




ATr Inhibitor in 
Combination 
With Olaparib in 
Gynaecological 
Cancers With 
ARId1A Loss or 
no Loss (ATARI)
II 40 AZD6738 (ATR 
inhibitor) Olaparib
Experimental: 1A: AZD6738 Women with 
relapsed ovarian (fallopian tube/primary 
peritoneal) and endometrial (uterus) 
clear cell carcinomas with loss of 




Experimental: 1B: AZD6738 + olaparib. 
In second stage of trial, opening of 
this cohort depends on response rate 
in cohort 1A during first stage of trial. 
Women with relapsed ovarian (fallopian 
tube/primary peritoneal) and endometrial 
(uterus) clear cell carcinomas with loss 
of ARID1A expression treated with 
AZD6738 in combination with olaparib
Experimental: 2: AZD6738 + olaparib. 
Women with relapsed ovarian (fallopian 
tube/primary peritoneal) and endometrial 
(uterus) clear cell carcinomas with NO 
loss of ARID1A expression treated with 
AZD6738 in combination with olaparib
Experimental: 3: AZD6738 + olaparib. 
Women with other rare relapsed 
gynaecological cancers (endometrioid 
ovarian carcinoma, endometrioid 
endometrial carcinoma, cervical 
adenocarcinoma, cervical squamous, 
ovarian carcinosarcoma and endometrial 
carcinosarcoma) irrespective of ARID1A 










II 35 Dasatinib - Endometrial clear cell adenocarcinoma ORR NCT02059265, 
active, not 
recruiting
- Ovarian clear cell cystadenocarcinoma
- Recurrent fallopian tube carcinoma
- Recurrent ovarian carcinoma
- Recurrent primary peritoneal 
carcinoma
- Recurrent uterine corpus carcinoma
Patients receive dasatinib PO QD 
on days 1-28. Courses repeat every 
28 days in the absence of disease 
progression or unacceptable toxicity
Table 3 (continued)
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I/II 166 PLX2853 (BRD4 
inhibitor)







• Ovarian clear cell carcinoma
• Non-Hodgkin lymphoma
• Advanced malignancies
• Solid tumor • Area under the 
concentration-time 
curve (AUC)
• Diffuse large B cell lymphoma




Phase 1b (dose escalation): up to 30 
subjects with advanced malignancies
• Time to peak 
concentration 
(Tmax)
Phase 2a (dose expansion): there will 
be 5 total expansion cohorts. Either 
10 or 29 subjects per cohort in each 
of 4 expansion cohorts: advanced 
SCLC, uveal melanoma, OCCC, and 
any other advanced malignancy with a 
known ARID1A mutation (between 40 
to 116 subjects total for the solid tumor 
expansion phase). For the 5th expansion 
cohort, up to 20 subjects may be 
enrolled for NHL
• Half life (t1/2) 




• Change in disease 
burden using 
RECIST 1.1 (solid 








II 86 Tazemetostat 
(EZH2-inhibitor)




• FIGO Grade 2 Endometrial 
Endometrioid Adenocarcinoma
• Recurrent endometrial endometrioid 
adenocarcinoma
• Recurrent ovarian carcinoma
• Recurrent ovarian clear cell 
adenocarcinoma
• Recurrent ovarian endometrioid 
adenocarcinoma
• Recurrent uterine corpus carcinoma
Patients receive tazemetostat PO BID on 
days 1–28. Cycles repeat every 28 days 
in the absence of disease progression or 
unacceptable
Table 3 (continued)
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based chemotherapies, but the results of the different 
mainly retrospective studies are conflicting and a possible 
association remains to be elucidated (135-139).
Besides the very intensively and successfully investigated 
PARP inhibitors, which have led to a dramatic improvement 
in the treatment of ovarian cancer and beyond, several 
clinical trials investigating ATR inhibitors and inhibitors 
of the PI3K/Akt/mTOR-pathway are currently ongoing 
in gynecologic cancers, some of them with molecular 
subanalyses or stratification including ARID1A (Table 3). 
In a Phase II trial of everolimus plus bevacizumab in 
advanced non-clear cell renal cell carcinoma there was a net 
benefit in tumors with papillary features with an ORR of 
43% vs. 11%, a median PFS of 12.9 vs. 1.9 months, and an 
overall survival of 28.2 vs. 9.3 months (P<0.001) compared 
to non-clear cell renal cell carcinoma without papillary 
features. Of note, five of the fourteen tumors with papillary 
features harbored somatic mutations in ARID1A and all 
five patients achieved treatment benefit (140). In a recently 
published Phase II trial of everolimus and bevacizumab in 
recurrent ovarian, peritoneal, and fallopian tube cancer, 
two of the nine responders were OCCC cases which 
both harbored mutations in ARID1A and PI3K-mediated 
activations of the mTOR-pathway. Three other responders 
had serous ovarian cancer with mutations in the homologous 
recombination pathway. It was noted that the two OCCC 
were among the patients staying on treatment for the 
longest with 11 and 15 cycles of treatment respectively (141). 
Although the combination of bevacizumab plus everolimus, 
compared to bevacizumab alone, did not improve PFS or 
OS in recurrent or persistent ovarian, fallopian tube or 
peritoneal carcinoma in a randomized Phase II trial (142), 
these observations indicate a possible benefit in certain 
subgroups such as ARID1A mutated OCCC.
Dasatinib is already approved for leukemia treatment and 
is currently under investigation for various solid tumors. A 
phase-II trial evaluating dasatinib in recurrent or persistent 
EOC showed limited efficacy but this study did not assess 
ARID1A status in the tumors (111). 
After the first generation of EZH2 inhibitors have 
shown toxicity in vivo, novel EZH2 inhibitors are currently 
the subject of clinical trials (143). Meanwhile, the NRG-
GY-014 phase II clinical trial assessing the EZH2-inhibitor 
tazemetostat in recurrent EnOC or OCC, as well as 
recurrent low-grade endometrioid endometrial carcinoma, 
is currently recruiting (144). 
Other alternatives for epigenetic targeting agents include 
HDAC2 inhibition, e.g., with vorinostat, or the HDAC6 
inhibitor ricolinostat (ACY-1215), which has been well 
tolerated by patients with relapsed or refractory multiple 
myeloma in a phase-1b trial (102,145). Furthermore, 
there is preclinical evidence of synergies between HDAC-
inhibitors and anti-PD-L1 immune checkpoint blockade 
in ARID1A-deficient ovarian cancer which may be a 
promising combination to be evaluated in future clinical 
trials (146,147).
Inhibitors of the BET (bromodomain and extra terminal 
domain) family of proteins have been shown to inhibit the 
proliferation of ARID1A-mutated cancer cell lines in vitro 
as well as in patient-derived xenograft models (104). Several 
BET inhibitors such as iBET-762 are currently under 
evaluation in phase I-II trials (148).
Besides target therapies and immunotherapies, the 
assessment of ARID1A in OCCC patients may also be 
helpful in the choice of chemotherapy. Gemcitabine appears 
the most effective chemotherapy agent in platinum-resistant 
OCCC with response rate estimated to 66% (n=12) in a 
sub-group analysis of the MITO-9 study (149). This was 
confirmed in another small retrospective cohort from Japan 
(n=7) that showed that three ARID1A-deficient OCCC 
patients had a significantly longer progression-free survival 








A Study of 
ENMD-2076 in 
Ovarian Clear Cell 
Cancers





ENMD-2067 will be taken orally at a 
dose of 275 mg, once a day, everyday. 
Patients with a body surface area of less 
than 1.65 m
2
 will receive a starting dose 






Complete or partial 
response rate
OC, ovarian cancer; ORR, overall response rate; MTD, maximum tolerated dose; PFS, progression free survival; OS, overall survival.
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who were not (150).
Conclusions and future implications
Despite being one of the most frequent benign disease in 
women of reproductive age, endometriosis remains fairly 
enigmatic in its cause and even more concerning the factors 
that in rare cases may lead to malignant transformation. 
Many unresolved aspects in endometriosis-associated 
ovarian cancer remain to be addressed. This includes 
diagnosis and early detection of malignant transformation 
of endometriosis, identification of risk factors associated 
with development of ovarian cancer and stratification of 
women at increased risk.
Table 4 Some examples of recent or ongoing studies in benign gynecologic disease and cancer including the detection of ARID1A mutations (www. 
clinicaltrials.gov) 










• Case Group: clinical or surgical 
diagnosis of Endometriosis, 
patients undergoing surgical 
management (n=100) 
• Somatic cancer driver 
mutations in progesterone-





• Control Group: no 
Endometriosis (Pat. undergoing 
Laparoscopic Tubal Ligation) 
(n=35)
• Cancer driver mutations 
in eutopic versus ectopic 
endometrial tissue (cases vs. 
controls)
• Difference in DNA methylation 
PCR profile of endometriotic 
lesions in ectopic versus 
eutopic endometrium (cases vs. 
controls)
Lavage of the Uterine 
Cavity for the Diagnosis 
of Ovarian and Tubal 
Carcinoma and their 
Premalignant Changes
(LUDOC)
50 Interventional • Procedure: lavage of the 
Cavum uteri and proximal 
fallopian tubes
• Detection of EOCs by 
mutation analysis in the lavage 
of the uterine cavity
NCT02062697, 
completed
• Procedure: liquid-PAP smear • Detection of EOCs by 
mutation analysis of the liquid-
based Pap smear
Lavage of the Uterine 
Cavity for the Diagnosis 
of Ovarian and Tubal 
Carcinoma - Study 
of Sensitivity and 
Specificity (LUDOC II)
540 Interventional Ovarian epithelial cancer Detection of somatic mutation 
analysis in at least one of the 
analyzed genes in cells found in 




• Procedure: lavage of the 
Cavum uteri and proximal 
fallopian tubes
Diagnosing Ovarian and 
Endometrial Cancer 





• Case Group: cases undergoing 
surgery for endometrial or 
ovarian cancer
Detection of cancer-related 
mutations: diagnosis ovarian 
and endometrial cancers by 
detection of cancer-related 
mutation taken by brush 




• Control Group: cases 
undergoing hysterectomy and/or 
salpingectomy, oophorectomy 








Evaluate the Inhibitory Effects 
of Single Agent AZD2281 
(Olaparib), in Patients with Early-
stage Endometrial Carcinoma
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Recent knowledge advances about alterations involving 
the SWI/SNF complex and its subunit ARID1A lead to a 
better picture of the processes involved in endometriosis and 
the carcinogenesis of EAOC. The dramatic improvement 
in ovarian cancer therapy achieved through intensive 
investigation of PARP inhibitors has undoubtedly boosted 
the research of new target therapies in ovarian cancer. New 
approaches are likely to soon translate into clinical research. 
Since inflammatory and epigenetic processes seem to play 
a predominant role in the pathogenesis of endometriosis-
associated ovarian carcinomas, which mainly account for the 
subtypes OCCC and EnOC, immune checkpoint inhibitors 
and targeting the PI3K pathway as well as epigenetic 
treatment approaches may play an important role in the 
treatment of these tumor entities. Further clinical research 
based on the specific molecular features of these tumor 
subtypes, such as e.g., umbrella or basket trials, will be crucial 
to elucidate the potential role of these treatment approaches. 
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